Statements (85)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
Opioid receptor antagonist
|
| gptkbp:advocates_for |
Promotes awareness and access.
Supported by advocacy groups. |
| gptkbp:availability |
Prescription only
Available in pharmacies. Available in some school districts. |
| gptkbp:brand |
gptkb:Zimhi
|
| gptkbp:campaigns |
Promoted by health organizations.
|
| gptkbp:category |
Emergency antidote
|
| gptkbp:class |
Opioid antagonists
|
| gptkbp:clinical_trial |
Emergency medicine
Addiction treatment NC T04512345 NC T04567890 |
| gptkbp:community_engagement |
Engages community stakeholders.
|
| gptkbp:community_involvement |
Distributed in at-risk communities.
|
| gptkbp:community_programs |
Distributed through community programs.
|
| gptkbp:contraindication |
Hypersensitivity to naloxone
|
| gptkbp:dosage_form |
Pre-filled syringe
|
| gptkbp:economic_impact |
Significantly reduces mortality.
|
| gptkbp:education |
Instructions for use provided.
|
| gptkbp:educational_programs |
Provided to patients.
|
| gptkbp:effective_date |
2021-01-15
FDA approved |
| gptkbp:emergency_services |
Available in emergency kits.
Included in emergency plans. Provided to laypersons. Training for emergency responders. Used by first responders. |
| gptkbp:formulation |
Solution
Injection |
| gptkbp:has_programs |
Available for users.
|
| gptkbp:healthcare |
Effective public health intervention.
Improves access to treatment. Influences public health policy. Reduces opioid overdose deaths. Training for providers. |
| https://www.w3.org/2000/01/rdf-schema#label |
Zimhi
|
| gptkbp:indication |
Emergency treatment of known or suspected opioid overdose.
|
| gptkbp:ingredients |
gptkb:Naloxone
|
| gptkbp:interacts_with |
May interact with opioids.
|
| gptkbp:invention |
Patent protected
|
| gptkbp:is_compatible_with |
Certain medications
|
| gptkbp:is_monitored_by |
Post-administration monitoring.
|
| gptkbp:is_used_for |
Opioid overdose
|
| gptkbp:manager |
Intramuscular
Intravenous Subcutaneous Intranasal |
| gptkbp:manufacturer |
Zimhi Pharmaceuticals
|
| gptkbp:marketed_as |
Zimhi brand
|
| gptkbp:packaging |
Single-dose vial
|
| gptkbp:partnerships |
Collaborations with NG Os.
|
| gptkbp:pharmacokinetics |
Rapid onset of action
Reverses opioid effects |
| gptkbp:population |
gptkb:hospital
Adults |
| gptkbp:previous_name |
Naloxone hydrochloride
|
| gptkbp:price |
Varies by pharmacy
|
| gptkbp:provides_information_on |
Follow local health authority guidelines.
Recommended in opioid overdose protocols. |
| gptkbp:public_awareness |
Increased awareness of opioid crisis.
|
| gptkbp:receives_funding_from |
Funded by government grants.
|
| gptkbp:regulatory_compliance |
Controlled substance.
|
| gptkbp:requires |
Available on FDA website
|
| gptkbp:research |
Ongoing studies on effectiveness
|
| gptkbp:safety_features |
Generally well tolerated.
|
| gptkbp:scholarships |
Support groups available.
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
gptkb:Nausea
Dizziness Vomiting Headache Cardiovascular effects Respiratory depression Withdrawal symptoms |
| gptkbp:storage |
Room temperature
|
| gptkbp:sustainability_initiatives |
Supports research on opioid use.
|
| gptkbp:training |
Conducted for healthcare providers.
Yes, for administration. |
| gptkbp:treatment |
Enhances patient outcomes.
Improves survival rates. |
| gptkbp:bfsParent |
gptkb:naloxone
|
| gptkbp:bfsLayer |
6
|